Share

May 2021; 8 (3) ArticleOpen Access

Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis

Tomas Uher, Jan Krasensky, Charles Malpas, Niels Bergsland, Michael G. Dwyer, Eva Kubala Havrdova, Manuela Vaneckova, Dana Horakova, Robert Zivadinov, Tomas Kalincik
First published March 16, 2021, DOI: https://doi.org/10.1212/NXI.0000000000000979
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
933

Share

Article Information

vol. 8 no. 3 e979
DOI: 
https://doi.org/10.1212/NXI.0000000000000979
PubMed: 
33727311
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received January 15, 2020
  • Accepted in final form January 5, 2021
  • First Published March 16, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Tomas Uher, MD, PhD,
    2. Jan Krasensky, MS (jan.krasensky{at}vfn.cz),
    3. Charles Malpas, MPsych, PhD (charles.malpas{at}unimelb.edu.au),
    4. Niels Bergsland, MS, PhD (npbergsland{at}bnac.net),
    5. Michael G. Dwyer, MS, PhD (mgdwyer{at}bnac.net),
    6. Eva Kubala Havrdova, MD, PhD (eva.havrdova{at}gmail.com),
    7. Manuela Vaneckova, MD, PhD (man.van{at}post.cz),
    8. Dana Horakova, MD, PhD (dana.horak{at}post.cz),
    9. Robert Zivadinov, MD, PhD (rzivadinov{at}bnac.net) and
    10. Tomas Kalincik, MD, PhD (tomas.kalincik{at}unimelb.edu.au)
  1. Tomas Uher, MD, PhD,
    2. Scientific Advisory Boards:

    1. Sanofi - advisory board 1/2020

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Financial support for conference travel and speaker honoraria from Biogen Idec, Novartis, Roche, Sanofi and Merck Serono.

    Editorial Boards:

    1. Activitas Nervosa Superior: Associate Editor from 2018 Journal of Neuroimaging: Editorial Board from 2020 Frontiers In Neurology: Review Editor from 2020 Frontiers In Behavioral Neuroscience: Review Editor from 2020

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen Sanofi (GZ-2017-11718)

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Charles University Grant Agency (GAUK) Czech Ministry of Education project Progres Czech Ministry of Health project

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Jan Krasensky, MS (jan.krasensky{at}vfn.cz),
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Biogen

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Charles Malpas, MPsych, PhD (charles.malpas{at}unimelb.edu.au),
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Niels Bergsland, MS, PhD (npbergsland{at}bnac.net),
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 1) Journal of Neuroimaging, Section editor for multiple sclerosis, 2018-present 2) PLOS ONE, Academic Editor, 2018-present 3) Journal of Magnetic Resonance Imaging, Associate Editor, 2018-present 4) Frontiers in Neurology, Associate Editor, 2020-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Michael G. Dwyer, MS, PhD (mgdwyer{at}bnac.net),
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Assistant Editor, Journal of Neuroimaging

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Protembis GmbH (2) EMD Serono (3) Keystone Heart

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis (2) Celgene (3) Protembis (4) Keystone Heart (5) Bristol Meyers Squibb

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Eva Kubala Havrdova, MD, PhD (eva.havrdova{at}gmail.com),
    7. Scientific Advisory Boards:

    1. 1. Biogen 2. Novartis 3. Genzyme 4. Actelion 5. Celgene

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Biogen 2. Novartis 3. Celgene 4. Genzyme 5. Actelion 6. Roche 7. Merck Serono

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. Biogen 2. Novartis 3. Celgene 4. Genzyme 5. Actelion 6. Roche 7. Merck Serono

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1. European Commission Grant: ABIRISK - IMI (2012-2016), investigator 2. Czech Ministry of Education: PROGRES Q27/LF1 (2017- 2022), investigator

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Biogen - Expert witness, 2019

  7. Manuela Vaneckova, MD, PhD (man.van{at}post.cz),
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Biogen Idec, Novartis,Teva, Roche, Genzyme

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biogen Idec

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen Idec

    Research Support, Government Entities:

    1. Czech Ministries of Health - RVO-VFN64165

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Dana Horakova, MD, PhD (dana.horak{at}post.cz),
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Dr. Horakova received compensation for travel, speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Roche, and Sanofi.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Support for research activities from Biogen Idec.

    Research Support, Government Entities:

    1. Supported by Czech Ministries of Education and Health [PRVOUK-P26/LF1/4].

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Robert Zivadinov, MD, PhD (rzivadinov{at}bnac.net) and
    10. Scientific Advisory Boards:

    1. R Zivadinov received personal compensation from Genzyme-Sanofi, Celgene and Novartis for serving on scientific advisory board.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. R Zivadinov received personal compensation from EMD Serono, Inc., Novartis, Sanofi-Genzyme,Celgene for speaking

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. R Zivadinov received personal compensation from EMD Serono, Inc., Novartis, Keystone Heart, Sanofi-Genzyme for consulting fees.

    Speakers' Bureaus:

    1. R Zivadinov received personal compensation from EMD Serono, Inc., BMS, Novartis, Sanofi-Genzyme for speaking

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Zivadinov: financial support for research activities from EMD Serono, Inc., Novartis, Sanofi-Genzyme,Mapi Pharma, Celgene and Protembis, Keystone Heart.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Tomas Kalincik, MD, PhD (tomas.kalincik{at}unimelb.edu.au)
    11. Scientific Advisory Boards:

    1. (1) chair of the MSBase Scientific Leadership Group, (2) Novartis, (3) Merck, (4) Biogen, (5) Roche, (6) Genzyme-Sanofi, (7) Celgene

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis, compensation for travel and speaker honoraria (2) Biogen, compensation for travel and speaker honoraria (3) Genzyme-Sanofi, compensation for travel and speaker honoraria (4) Teva, speaker honoraria (5) Merck, compensation for travel and speaker honoraria (6) WebMD Global, speaker honoraria (7) Roche, speaker honoraria (8) BioCSL, speaker honoraria

    Editorial Boards:

    1. (1) Multiple Sclerosis Journal, editorial board member, since 2018 (2) CNS Drugs, editorial board member, since 2020 (3) Neurology and Clinical Practice, editorial board member, since 2020 (4) BMC Neurology, associate editor 2017-2018 (5) Frontiers in Neurology, reviewer editor 2017-2018

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. (1) Novartis, (2) Biogen, (3) Genzyme-Sanofi, (4) Teva, (5) Merck, (6) WebMD Global, (7) Roche, (8) BioCSL, (9) Roche, (10) BMS/Celgene

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen, (2) Merck, (3) BMS/Celgene

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. (1) University of Melbourne

    Research Support, Foundations and Societies:

    1. (1) National Health and Medical Research Council, (2) MS Research Australia, (3) Medical Research Future Fund, (4) Australian Research Council, (5) MS Society, UK, (6) EDMUS and ARSEP Foundations

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the CORe (T.U., C.M., T.K.), Department of Medicine, the University of Melbourne, VIC, Australia; Department of Neurology and Center of Clinical Neuroscience (T.U., E.K.H., D.H.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital; Department of Radiology (J.K., M.V.), Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Czech Republic; Buffalo Neuroimaging Analysis Center (N.B., M.G.D., R.Z.), Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York; IRCCS (N.B.), Fondazione Don Carlo Gnocchi, Milan, Italy; Center for Biomedical Imaging at Clinical Translational Science Institute (R.Z.), University at Buffalo, State University of New York; and Melbourne MS Centre (T.K.), Department of Neurology, the Royal Melbourne Hospital, VIC, Australia.
  1. Correspondence
    Dr. Uher tomas.uher{at}vfn.cz
View Full Text

Article usage

Article usage: March 2021 to December 2022

AbstractFullPdfSource
Mar 202157503132Highwire
Apr 20211717669Highwire
May 2021454646Highwire
Jun 2021829723Highwire
Jul 20211011223Highwire
Aug 2021414920Highwire
Sep 2021513926Highwire
Oct 20211131559Highwire
Nov 2021936171Highwire
Dec 2021614133Highwire
Jan 2022723940Highwire
Feb 2022620229Highwire
Mar 20221428747Highwire
Apr 20221421834Highwire
May 2022821537Highwire
Jun 20221323330Highwire
Jul 20221223932Highwire
Aug 20221124238Highwire
Sep 20221126336Highwire
Oct 20221027544Highwire
Nov 20221225536Highwire
Dec 2022816628Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me